Skip to content

Cancer Genetics and Genomics Laboratory

BC Cancer

  • Home
  • Hematological
    • Acute Lymphoblastic Leukemia (Ph positive)
    • Acute Myeloid Leukemia (AML)
    • Acute Promyelocytic Leukemia (APL)
      • APL – FISH (Dx)
      • APL – RT-ddPCR (MRD)
      • APL – RTPCR
    • Chimerism
    • Chronic Lymphocytic Leukemia/Lymphoma (CLL)
    • Chronic Myeloid Leukemia (CML)
      • CML – FISH (Dx)
      • CML – QRTPCR
      • CML – RTPCR
      • CML – Kinase Domain
    • Lymphoma
      • Anaplastic Large Cell
      • Burkitt
      • Follicular
      • High-Grade B-Cell
      • IRF4 B-Cell Lymphoma
      • MALT
      • Mantle Cell
      • NHL – B/T-cell Clonality
    • Lymphoid and Myeloid Neoplasm with Eosinophilia
    • Multiple Myeloma
    • Myelodysplastic Syndrome (MDS)
    • Myeloproliferative Neoplasm (MPN)
  • Solid Tumour
    • Colorectal Cancer
      • OncoPanel
      • BRAF V600
    • CNS
      • Focus Panel
      • Glioblastoma Multiforme (GBM)
      • Oligodendroglioma (ODG) 1p/19q FISH
    • Lung Cancer
      • ALK FISH
      • EGFR T790M (Plasma)
      • Focus Panel
      • ROS1 FISH
    • Melanoma
      • OncoPanel
      • Focus Panel
      • BRAF V600
    • Sarcoma
      • Alveolar Rhabdomyosarcoma (ARMS)
      • Clear Cell Sarcoma
      • Dermatofibrosarcoma protuberens (DFSP)
      • Ewing Sarcoma
      • Liposarcoma
      • Low Grade Fibromyxoid Sarcoma
      • Myxoid Liposarcoma
      • Synovial Sarcoma
    • Prostate Cancer
      • OncoPanel
    • DPYD Screening
  • Hereditary
    • Mainstreamed Hereditary Cancer Testing
  • Genes/Probes/Panels
    • Hereditary Cancer Panel
    • Myeloid Panel
    • OncoPanel
    • Focus Panel
    • Gene/Probe List
  • Guidelines
    • Specimens
    • Variants
    • FAQ
  • Studies
    • PREDICTm
    • [CLOSED]
  • Requisitions
  • Updates
  • Contact

Acute Myeloid Leukemia MRD testing

2023/03/222022/04/01 by Curtis Hughesman

The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer will begin offering minimal/measurable residual disease (MRD) testing for select patients with Acute Myeloid Leukemia (AML) starting the week of April 11, 2022. Key points regarding this new testing are outlined in the memo below.

AML MRD MemoDownload
Categories Uncategorized
Launch of Focus Panel NGS testing
Metastatic Prostate Cancer
© 2025 Cancer Genetics and Genomics Laboratory • Built with GeneratePress